EMA Authorised: Hexacima (hepatitis B surface antigen;Diphtheria toxoid;Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin;poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett);Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein;tetanus toxoid) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorised Hexacima, a combination vaccine covering hepatitis B, diphtheria, pertussis, poliomyelitis, Haemophilus influenzae type b, tetanus, intended for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Poliomyelitis
• Whooping Cough

Drugs mentioned

• Hexacima

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Tetanus;Immunization;Meningitis, Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria. MAH: Sanofi Winthrop Industrie. Decision date: 25/06/2026